Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Apr 4;4(7):1107–1117. doi: 10.1158/1940-6207.CAPR-10-0306

Fig. 3.

Fig. 3

A, microscopic images of MCF-10A cells after 24-hour treatment with DMSO (control), TGFβ and TNFα (10 ng/mL of each), 2.5 μmol/L BITC, and combined TGFβ/TNFα and BITC (×100 magnification). Immunoblotting for (B) E-cadherin, vimentin, and fibronectin, and (C) β-catenin, p53, and Rb using lysates from MCF-10A cells treated for 12 hours with DMSO (control), TGFβ and TNFα (10 ng/mL of each), 2.5 μmol/L BITC, and combined TGFβ/TNFα and BITC. Number on top of the immunoreactive band represents fold change in protein level relative to DMSO-treated control (first lane from left). Each experiment was repeated at least twice and representative data from one such experiment are shown.

HHS Vulnerability Disclosure